CLINICAL_TRIALS
research
· 2026-01-22
Clinical Trial Update: Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy [EARLY_Phase 1]
Summary
A Phase 1 trial for REGEND007 cell therapy targeting idiopathic pulmonary fibrosis is not yet recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Regend Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING